Clinical trials: Atorvastatin
Venous Thromboembolism
Statin Use in Patients With Acute VTE
This is a pilot, randomized, open-labelled study. Eligible patients will be enrolled and randomized 1:1 into "anticoagulation" arm or "anticoagulation plus atorvastatin" arm, with atorvastatin given at 40 mg orally daily for 3…
- Trial name
- NCT02331095
- Testing
- Atorvastatin, Anticoagulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University
Type 1 Diabetes Mellitus, Dyslipidemia
Treatment Effects of Atorvastatin on Hemostasis and Skin Microcirculation in Patients With Type 1 Diabetes
Patients with type 1 diabetes are at increased risk of vascular complications both in the micro- and macrocirculation. Hyperglycemia plays a major role in the development of these vascular complications, but other factors such…
- Trial name
- NCT01497912
- Testing
- Atorvastatin
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karolinska Institutet
Metastatic Prostate Cancer, Recurrent Prostate Cancer
Impact of Atorvastatin on Prostate Cancer Progression During ADT
This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.
- Trial name
- ESTO2 (NCT04026230)
- Testing
- Atorvastatin 80mg
- Where
- 10 sites in Denmark, Estonia and 2 more
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Coronary Artery Disease
PCSK9 inhibitoRs for Early Passivation of coRonary athEroSclerotic plaqueS in Acute Coronary Syndromes (REPRESS)
In this prospective, multicenter, open-label trial, 212 ACS patients will be randomized 1:1 to either the "PCSK9i early" intensified therapy group (initial addition of PCSK9i to moderate-intensity statin) or the…
- Trial name
- NCT06791031
- Testing
- PCSK9 inhibitor (PCSK9i)
- Volunteers
- 212 people
- Sponsor
- West China Hospital
Atherosclerotic Cardiovascular Disease
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab
Primary Objective: To compare the effect of alirocumab with placebo on the occurrence of cardiovascular (CV) events (composite endpoint of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), fatal and…
- Trial name
- NCT01663402
- Testing
- Alirocumab, LMT
- Where
- 1,388 sites in United States, Argentina and 55 more
- Volunteers
- 18,924 people
- Sponsor
- Sanofi
Fatty Liver, Dyslipidemias
Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease
The purpose of the study is to compare the impact of atorvastatin 20mg qd and Vitamin E 300mg qd therapy on liver fat content in patients with type 2 diabetes associated with high LDL-C and non-alcoholic fatty liver disease.
- Conditions
- Fatty Liver, Dyslipidemias, Diabetes Mellitus
- Trial name
- NCT01720719
- Testing
- atorvastatin, Vitamin E
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xin Gao
Drug-drug Interactions
A Clinical Trial to Evaluate the Drug-drug Interactions of Co-administered 'HUC2-744-A' and 'HUC2-744-B' in Healthy Adult Volunteers
This study aims to evaluate the pharmacokinetic interactions between HUC2-744-A and HUC2-744-B following monotherapy or co-administration under multiple-dose conditions.
- Trial name
- DDI (NCT07784608)
- Testing
- Atorvastatin Calcium, Telmisartan
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Huons Co., Ltd.
Hypertension
Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients
The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.
- Trial name
- NCT02254824
- Testing
- Xuezhikang, Atorvastatin, Lifestyle modification
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Chest Wall Tumor, Breast Cancer
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Radiation therapy is an essential treatment for tumors in the chest area, including breast, lung, esophageal, mediastinal cancers, and spine metastases.
- Conditions
- Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- NCT07685938
- Testing
- Atorvastatin and Lisinopril
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Myocardial Infarction, Dyslipidemias
Early Alirocumab to Reduce LDL-C in Myocardial Infarction
The EARLY trial is a phase IV, investigator initiated, international, multicentre study that will investigate if early use of alirocumab 150mg plus atorvastatin 80mg (enhanced care) will have a greater effect than atorvastatin…
- Trial name
- EARLY (NCT03750760)
- Testing
- Alirocumab, Atorvastatin 80mg, Ezetimibe 10mg
- Where
- 17 sites in United Kingdom
- Sponsor
- Imperial College London
Acute Coronary Syndromes, Dyslipidemia
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein…
- Trial name
- EARLY-BIRD ACS (NCT07824323)
- Testing
- bempedoic acid, Ezetimibe, High-Intensity Statin Therapy
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Taipei Medical University Hospital
Hypercholesterolemia
Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy
Primary Objective: To evaluate the effect of alirocumab (SAR236553/REGN727) on low-density lipoprotein cholesterol (LDL-C) levels after 12 weeks of treatment in comparison with placebo in participants with LDL-C ≥ 100 mg/dL (≥…
- Trial name
- NCT01288443
- Testing
- Alirocumab, Atorvastatin
- Where
- 38 sites in United States
- Volunteers
- 183 people
- Sponsor
- Sanofi
Alzheimer's Disease
Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study
Specific Aim: Demonstrate that statins have an effect on cerebral blood flow and neuronal activity
- Trial name
- NCT03411291
- Testing
- MRI, MR Spectroscopy, MR Perfusion
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Cedars-Sinai Medical Center
Renal Insufficiency
Atorvastatin in the Recipient's Kidney Graft From a Living Donor
Renal insufficiency is a priority disease in the health system, which may require renal replacement therapy based on kidney transplantation, which is considered as therapy of choice.
- Trial name
- ATORV15 (NCT02522117)
- Testing
- Atorvastatin
- Where
- Mexico
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Myalgia, Hypercholesterolemia
Study of the Safety and Tolerability Associated With PPD10558 Versus Atorvastatin in Patients Previously Intolerant to Statins Due to Statin-associated Myalgia (SAM)
The purpose of this study is to assess the incidence of statin-associated myalgia (SAM) with treatment with PPD10558 versus atorvastatin in patients previously intolerant to statins.
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Trial name
- NCT01279590
- Testing
- PPD10558, Atorvastatin
- Where
- 67 sites in United States
- Volunteers
- 282 people
- Sponsor
- Furiex Pharmaceuticals, Inc
Acute Coronary Syndrome
VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
- Trial name
- VISTA-16 (NCT01130246)
- Testing
- A-002, varespladib methyl
- Where
- 362 sites in United States, Australia and 15 more
- Volunteers
- 5,189 people
- Sponsor
- Anthera Pharmaceuticals
Obesity, Dyslipidemia
Regulation of Lipoprotein Metabolism in Obese Men
Visceral obesity is strongly associated with dyslipidaemia (hypertriglyceridaemia, low HDL-cholesterol and mildly elevated LDL-cholesterol) and insulin resistance, key characteristics of metabolic syndrome (MetS).
- Conditions
- Obesity, Dyslipidemia, Insulin Resistance
- Trial name
- NCT00392717
- Testing
- Atorvastatin, Fish oils
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- The University of Western Australia
Cerebral Infarction
Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period.
This is a randomized, double-blind study. Human umbilical cord mesenchymal stem cells (hUC-MSC) will be treated on cerebral infarction patients, and evaluates their neurological function of convalescent period.
- Trial name
- NCT03176498
- Testing
- Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Atrial Fibrillation, Arrhythmia
The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation
To investigate whether statin therapy utilizing the drug Lipitor (atorvastatin) might be effective in preventing short-and long-term atrial fibrillation (AF) following a left atrial ablation procedure.
- Conditions
- Atrial Fibrillation, Arrhythmia, Inflammation, Endothelial Dysfunction
- Trial name
- ATTAC (NCT00579098)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Mayo Clinic
HDL Cholesterol
Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)
Summary: Background: There is a lot of interest in the function and role of HDL to prevent and mitigate atherosclerosis in patients who are at or near LDLc targets.
- Trial name
- NCT00736463
- Testing
- Simvastatin, Atorvastatin 80 mg
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Oregon Health and Science University